Related Experiment Videos
Long-term survival in small cell lung carcinoma
R N Hitchins1, J Phillips, R L Woods
1Royal North Shore Hospital, NSW.
Australian and New Zealand Journal of Medicine
|February 1, 1988
Summary
While some small cell lung carcinoma patients achieve long-term survival, 30-month disease-free survival is not definitive proof of cure due to late relapses. Aggressive therapies offer potential cure without excessive late toxicity.
Area of Science:
- Oncology
- Pulmonology
- Cancer Research
Background:
- Small cell lung carcinoma (SCLC) is an aggressive cancer with historically poor prognosis.
- Treatment often involves combination chemotherapy and radiotherapy, but long-term outcomes remain a concern.
Purpose of the Study:
- To evaluate the long-term outcomes and survival rates in patients with small cell lung carcinoma treated with chemotherapy, with or without radiotherapy.
- To assess the possibility of cure and the occurrence of late relapses in SCLC survivors.
Main Methods:
- Retrospective analysis of 208 patients with small cell lung carcinoma.
- Assessment of outcomes 2-7 years post-treatment with combination chemotherapy +/- chest and cranial radiotherapy.
Main Results:
- 6.7% (14/208) of patients survived cancer-free for ≥30 months.
- Of the 14 long-term survivors, 9 had limited disease and 4 had extensive disease with a single metastatic site.
- Late relapses occurred in 5 patients more than 30 months post-diagnosis, indicating 30-month survival is insufficient to confirm cure.
Conclusions:
- A small proportion of small cell lung carcinoma patients can be cured, but late relapses necessitate longer follow-up.
- Aggressive treatment regimens appear to offer benefits of long-term survival and potential cure without significant late toxicity.
- Long-term survivors maintained active lifestyles, suggesting manageable late effects.